Methyltransferase METTL1 regulates MSC mRNA stability via m7G modification in acute pancreatitis

Xufeng Tao1, Xiaonan Zhang2,3, Fangyue Guo2

  • 1Department of Pharmacy, First Affiliated Hospital of Dalian Medical University, Dalian, China.

Cell Death & Disease
|June 22, 2026
PubMed

Insights

This study uncovers a new RNA modification pathway involving METTL1 and m7G in acute pancreatitis (AP). Targeting this METTL1-m7G-MSC-TNF axis may offer new treatments for AP and other inflammatory diseases.

Area of Science:

  • Epitranscriptomics
  • Molecular Biology
  • Inflammation Research

Background:

  • Acute pancreatitis (AP) is a severe inflammatory condition with poorly understood molecular underpinnings.
  • Epitranscriptomic modifications, like N7-methylguanosine (m7G), are emerging as critical regulators in disease pathogenesis.

Purpose of the Study:

  • To elucidate the role of METTL1-mediated m7G RNA modification in the pathogenesis of acute pancreatitis.
  • To identify key molecular targets and signaling pathways involved in this epitranscriptomic regulation during AP.

Main Methods:

  • Integrated multi-omics analysis (m7G methylome mapping and transcriptome profiling).
  • In vivo studies using sodium taurocholate-induced AP mouse models with pancreas-targeted Mettl1 knockdown.
  • In vitro experiments using LPS-polarized macrophages and STC-injured pancreatic acinar cells.
  • Mechanistic studies employing a catalytic-dead METTL1 mutant.

Main Results:

  • Elevated METTL1 expression and global m7G levels were observed in AP patients and models.
  • Musculin (MSC) was identified as a key target stabilized by METTL1-mediated m7G modification.
  • MSC upregulation activated TNF signaling, promoting M1 macrophage polarization and acinar cell injury.
  • Pancreas-specific Mettl1 knockdown significantly reduced AP severity in vivo.

Conclusions:

  • A novel METTL1-m7G-MSC-TNF signaling axis drives AP progression.
  • METTL1-mediated epitranscriptomic modification is crucial for inflammatory responses in AP.
  • Targeting the METTL1 pathway presents a potential therapeutic strategy for AP and related inflammatory diseases.

Related Concept Videos